According to The Insight Partners' research, the Asia Pacific Infusion Pumps Market was valued at US$ 2,521.4 Million in 2025 and is expected to reach US$ 4,311.8 Million by 2034, registering a CAGR of 6.2% from 2026 to 2034.
Growing geriatric population and advancing technology in infusion pumps are among the critical factors attributed to drive the Asia Pacific infusion pumps market.
Precise medication administration for age-related ailments is crucial in both clinical and home settings. As individuals age, they become more susceptible to chronic diseases. According to the WHO, the number of people aged 60 and above globally is expected to rise from ~ 1.1 billion in 2023 to 1.4 billion by 2030 and 2.1 billion by 2050. The number of people aged 80 or older is projected to triple between 2020 and 2050, reaching 426 million, driven by longer life expectancies and declining birth rates. WHO data indicate that by 2030, one in six people worldwide will be aged 60 or over, with 80% residing in low- and middle-income countries where healthcare access is limited.
Cardiovascular disease is the leading cause of death worldwide, with 17.9 million annual fatalities. According to the 2025 Heart Disease & Stroke Statistics, among individuals aged 80 years and older, 85.9% of males and 85.1% of females have cardiovascular disease. In older adults with diabetes, insulin pumps deliver insulin just as effectively as they do in younger patients. An NIH study titled "Insulin Pump Therapy Is Equally Effective and Safe in Elderly and Young Type 1 Diabetes Patients" found that patients over 50 using insulin pumps had an average HbA1c level of 7.01%, showing that pump therapy is safe and effective across age groups.
Similarly, ambulatory pumps facilitate home-based therapy for conditions such as heart failure or osteoporosis, reducing hospital stays; the FDA emphasizes their role in minimizing risks for frail patients. Examples include using elastomeric pumps for post-surgical pain management in seniors or implantable pumps for Parkinson's medication. Together, these factors highlight the importance of infusion technology in supporting sustainable healthcare systems as populations continue to age globally.
On the contrary, product recalls and safety concerns hamper the growth of the Asia Pacific infusion pumps market.
Asia Pacific Infusion Pumps Market Segmentation Analysis:
- By Product, the Asia Pacific Infusion Pumps Market is segmented into IV infusion Pumps, Syringe Infusion Pumps, Volumetric infusion Pumps, Ambulatory Pumps, Patient-Controlled Analgesia (PCA) Pumps, Enteric Feeding Pumps, Disposable Elastomeric Pumps, and Others. The IV infusion Pumps segment is projected to expand at a CAGR of 5.8% during 2026 - 2034.
- By Customer, the Asia Pacific Infusion Pumps Market is segmented into Small Hospitals and Nursing Home, Standalone Hospitals, Tertiary Care Hospitals, and Hospital Chain. The Tertiary Care Hospitals segment is projected to expand at a CAGR of 6.7% during 2026 - 2034.
- By End User, the Asia Pacific Infusion Pumps Market is segmented into Anaesthesiologists, Critical Care Specialists, and Others. The Anaesthesiologists segment is projected to expand at a CAGR of 6.4% during 2026 - 2034.
By country, the Asia Pacific Infusion Pumps Market is categorized into China, Japan, India, South Korea, Australia, and the Rest of APAC. China is projected to expand at a CAGR of 6.6% during 2026 - 2034.
Key players operating in the Infusion Pumps Market are Terumo Corp, Baxter International Inc, ICU Medical Inc, Fresenius Kabi AG, B. Braun Melsungen AG, Becton Dickinson and Co, Shenzhen Mindray Bio-Medical Electronics Co Ltd, Shenzhen Comen Medical Instruments Co., Ltd., Allied Medical Limited, and Beijing KellyMed Co., Ltd., among others.
- In April 2024, Baxter International Inc. received US FDA 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform, which includes Baxter's syringe infusion pump with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite, enables clinicians to utilize a single, integrated system across various patient care settings. Offering the Novum IQ LVP in the US demonstrates Baxter's commitment to continued innovation in advancing infusion therapy.
- In August 2023, ICU Medical, Inc. received 510(k) regulatory clearance from the USFDA for the Plum Duo infusion pump with LifeShield infusion safety software. The Plum Duo pump and LifeShield software were available to customers in the US from early 2024. The Plum Duo pump is the newest addition to ICU Medical's portfolio of infusion devices and features a large color touch screen with a highly intuitive user interface and two channels capable of delivering up to four compatible IV medications.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com